Clinical trial
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage…
NCT00294190 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00294190 |
|---|---|
| Title | Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer |
| Official title | A Phase II Study Of Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer, Carcinoma, Small Cell |
| Intervention type | Drug |
| Interventions | Topotecan |
| Enrollment | 38 |
| Start date | Feb 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Jul 1, 2009 |
| First posted | Feb 20, 2006 |
| Last update posted | Dec 10, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: